Luca Warm

@lcwarm.bsky.social

8 months ago

#Recursion (Nasdaq #RXRX) Acquires Full Rights to #REV102, a Potential First-in-Class Oral #ENPP1 Inhibitor for #Hypophosphatasia

ir.recursion.com/news-release...